Skip to main content
PepStack
Wiki · Profile

Thymosin Beta-4 Sulfoxide

Tß4 Sulfoxide · TB4-SO

Wound Healing & RegenerationPreclinical

Thymosin Beta-4 Sulfoxide is a modified form of the peptide Thymosin Beta-4, primarily derived from monocytes in the presence of glucocorticoids. Researchers primarily study it for its role in modulating inflammatory responses and its interactions with actin, a key protein in cellular structure and movement. Key findings indicate that while oxidation of Thymosin Beta-4 reduces its ability to sequester actin, it enhances its extracellular signaling properties, particularly in inhibiting neutrophil chemotaxis and reducing inflammation in animal models. Additionally, studies suggest that the structural changes associated with oxidation may confer unique functional properties that differentiate it from its unmodified counterpart. Current research continues to explore its potential applications in anti-inflammatory therapies and the underlying mechanisms of its action.

Chemical Profile

Chemical Profile

Half-Life

INIntranasal

Not applicable

POOral

Poor bioavailability

Pharmacokinetic data is limited, with variability expected based on administration route.

Mechanism

Mechanism of Action

Thymosin beta-4 sulfoxide acts as an anti-inflammatory agent by inhibiting neutrophil chemotaxis and adhesion to endothelial cells, likely through modulation of the cytoskeletal dynamics involving actin. It is generated by monocytes in the presence of glucocorticoids and may engage signaling pathways associated with the inhibition of inflammatory responses, although the precise receptors and downstream signaling pathways remain to be fully elucidated. The oxidation of thymosin beta-4 enhances its extracellular signaling properties while attenuating its intracellular actin-sequestering activity, suggesting a dual role in cellular processes.

Research

3 Research Publications

231

Total Citations

1.0

Avg. Influence

2007

Latest

#01

Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids.

Young J D, et al. · Nature medicine · 1999

AnimalInfluence1.0
190
The study demonstrated that thymosin beta4 sulfoxide, generated by monocytes in the presence of glucocorticoids, acts as an anti-inflammatory agent by inhibiting neutrophil chemotaxis and reducing edema in mouse models.

Key findings

  1. 01Thymosin beta 4 sulfoxide is generated by monocytes when glucocorticoids are present.
  2. 02This molecule inhibits the movement of neutrophils, a type of immune cell involved in inflammation.
  3. 03In animal tests, thymosin beta 4 sulfoxide effectively reduced swelling caused by inflammation.
PubMed
#02

Thymosin beta4: actin regulation and more.

Yarmola Elena G, et al. · Annals of the New York Academy of Sciences · 2007

In Vitro
28
Researchers observed that thymosin beta(4) sulfoxide does not alter profilin binding but reduces the affinity to actin compared to intact thymosin beta(4), indicating the significance of methionine oxidation in its structural properties.

Key findings

  1. 01Researchers found that thymosin beta(4) forms a ternary complex with actin and profilin, affecting their interactions.
  2. 02The study observed that the presence of TMAO stabilizes thymosin beta(4) and increases its binding affinity to actin.
  3. 03Researchers noted that oxidation alters the structure of thymosin beta(4), impacting its properties and interactions.
PubMed
#03

Interactions of beta-thymosins, thymosin beta 4-sulfoxide, and N-terminally truncated thymosin beta 4 with actin studied by equilibrium centrifugation, chemical cross-linking and viscometry.

Huff T, et al. · European journal of biochemistry · 1995

In VitroInfluence1.0
13
Researchers observed that oxidation of thymosin beta 4 increases the dissociation constant with actin and inhibits polymerization, while truncated forms lose this ability, highlighting the importance of specific amino acid residues.

Key findings

  1. 01All beta-thymosins examined inhibit the polymerization of actin into filaments under high salt conditions.
  2. 02Oxidation and truncation of thymosin beta 4 reduce its ability to bind to actin, with significant loss of interaction when certain amino acids are removed.
  3. 03Only the oxidized form of thymosin beta 4 effectively inhibits actin polymerization, but requires a much higher concentration compared to the unmodified beta-thymosin.
PubMed
Safety

Safety & Handling

Research Gaps

No clinical trials in humans have been conducted to evaluate the efficacy and safety of thymosin beta-4 sulfoxide as an anti-inflammatory agent. Additionally, the long-term effects of thymosin beta-4 sulfoxide on immune response and potential side effects remain unknown, as well as the precise molecular mechanisms underlying its enhanced extracellular signaling properties compared to its native form.

Solubility

Thymosin Beta-4 Sulfoxide is soluble in water and DMSO.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not scheduled by the DEA.

🇦🇺AU

Not listed in the TGA schedules.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

3 total
1
95
1
99
1
07
Mechanism

Tools

Mechanism

Related Peptides

Track Thymosin Beta-4 Sulfoxide in PepStack

Log your research cycles, set reminders and visualize serum levels.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer